Semax

Semax Vials

Semax

Introduction

Semax Vials are research products designed exclusively for scientific investigations. Developed with meticulous care, these vials contain Semax, a synthetic peptide known for its potential neuroprotective and cognitive-enhancing properties.

Key Characteristics

Semax Vials feature a carefully measured dosage of Semax, a synthetic analog of the endogenous peptide ACTH(4-10). This product is intended for use in controlled laboratory settings to explore its impact on neural processes and cognitive functions.

Research Applications

Semax Vials provide a valuable tool for scientists and researchers exploring the intricate mechanisms of neurobiology. Applications include investigations into cognitive enhancement, neuroprotection, and potential therapeutic interventions for neurological disorders.

Research Benefits

Semax and Dopamine

Research suggests that Semax may modulate dopamine levels in the brain, influencing mood regulation and motivation. Studies have indicated a potential interaction between Semax and dopaminergic pathways, paving the way for further exploration into its impact on neuropsychiatric conditions.

Semax and Brain Health

The neuroprotective properties of Semax make it a compelling subject for research on overall brain health. Preliminary studies suggest that Semax may have a role in mitigating oxidative stress and inflammation, contributing to the maintenance of neuronal integrity.

Semax and Memory

Semax has demonstrated promising effects on memory and cognitive functions in preclinical studies. By targeting neural pathways associated with memory consolidation, Semax may offer insights into potential therapeutic avenues for memory-related disorders.

Summary

Semax Vials are cutting-edge research tools designed for the scientific community to explore the potential benefits of Semax in controlled laboratory settings. With a focus on neuroprotection, cognitive enhancement, and potential therapeutic applications, Semax Vials offer a valuable resource for advancing our understanding of brain function and neurological disorders. Researchers are encouraged to adhere to ethical guidelines and safety protocols while conducting experiments with Semax Vials.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005 Dec;30(12):1493-500. doi: 10.1007/s11064-005-8826-8. PMID: 16362768.

2. Asmarin IP, Nezavibat’ko VN, Miasoedov NF, Kamenskiĭ AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AIa, Koshelev VB, Riasina TV. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997 Mar-Apr;47(2):420-30. Russian. PMID: 9173745.

3. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat’ko VN, Zhuravleva EIu, Vanichkin AV. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. Russian. PMID: 11517472.